Atrys Health Net Margin
The Net Profit Margin of Atrys Health (ATRY.MC) as of Jul 26, 2026 is -71.13 %. In the previous year, Net Profit Margin was -14.94 % — a change of 376.24% (lower).
Get this data via API
Financial Data API
Net Margin
-71.13 %
YoY
376.24%
Last updated:
Net Profit Margin of Atrys Health is 2026 -71.13 % . Net Profit Margin of Atrys Health was 2025 -14.94 % . It decreases by 376.24% lower compared to the previous year.
Atrys Health's net margin stands at -71.1%, down from -19.2% several years earlier.
Access this data via the Eulerpool API
Atrys Health Stock analysis
What does Atrys Health do? Atrys Health SA is a leading provider of medical services, founded in 2007 in Madrid, Spain, as a spin-off company of the Clinica Universidad de Navarra. The company's goal is to connect the limitless world of science and technology with the human component of healthcare.
The business model of Atrys Health specializes in the development of products, services, and solutions in the field of medical imaging and cancer treatment. The company offers innovative technologies and medical services to help diagnose and treat patients better.
Atrys Health consists of different business divisions focusing on the needs of clinical practice, research and development, and biotechnological production. The company aims to improve the efficiency and effectiveness of diagnosis, imaging, and treatment technologies to maximize results.
The divisions of Atrys Health focus on various aspects of healthcare, including telemedicine, radiology, and proton therapy. Telemedicine provides a platform for remote treatments and medical consultation, improving access to specialists and enabling fast and effective diagnosis and treatment. The radiology division operates diagnostic centers specializing in medical imaging, equipped with the latest imaging technologies. The proton therapy division operates a proton therapy center in Madrid, offering advanced cancer treatment.
Atrys Health offers a range of products tailored to the needs of clinical practice, research and development, and biotechnological production. Their key products include Atrilab, a leading platform for precision oncology diagnostics, Auriculum, a technology for precise radiation in cancer treatments, and Vida Oncology, a software solution for cancer treatment management.
In conclusion, Atrys Health is a key player in medical imaging and cancer treatment, improving healthcare globally with advanced technologies and services. With their vision of combining innovative technologies with the human component of healthcare, Atrys Health will continue to lead in the healthcare industry. Atrys Health is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Atrys Health stock
Net Profit Margin of Atrys Health is -71.13 % in 2026.
Access this data via the Eulerpool API
Margins — Atrys Health
All Key Metrics — Atrys Health
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth